IP Library Granted Patent US 8,481,506
Granted Patent B2
US 8,481,506 · App. 12/517,760 · Granted Jul 9, 2013

Nucleic acids involved in viral infection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,481,506
App. No.
12/517,760
Granted
Jul 9, 2013
Kind
B2
Abstract

Provided herein are isolated viral and human nucleic acids associated with viral infection and various nucleic acid molecules relating thereto or derived therefrom. The nucleic acids may be useful for the prevention, treatment and diagnosis of viral infections.

Claims (18)

1. A method of reducing the amount of virus replication in a target cell, the method comprising introducing into a target cell infected with the virus an effective amount of a composition comprising an isolated nucleic acid, wherein the nucleic acid consists of:

(a) SEQ ID NO: 15,372;

(b) a DNA encoding (a), wherein the DNA is identical in length to (a);

(c) a sequence at least 80% identical to (a) or (b), wherein the sequence is 13-33 nucleotides in length; and

(d) the complement of any one of (a)-(c), wherein the complement is identical in length to (a).

2. The method of claim 1 , wherein the target cell is in vitro.

3. The method of claim 1 , wherein the target cell is in vivo.

4. The method of claim 1 , wherein a subject comprises the target cell.

5. The method of claim 1 , wherein the virus is hepatitis B virus.

6. A method of reducing the amount of virus replication in a target cell, the method comprising introducing into a target cell infected with the virus an effective amount of a composition comprising an isolated nucleic acid, wherein the nucleic acid consists of:

(a) SEQ ID NO: 15,385;

(b) a DNA encoding (a), wherein the DNA is identical in length to (a);

(c) a sequence at least 80% identical to (a) or (b), wherein the sequence is 45-200 nucleotides in length; and

(d) the complement of any one of (a)-(c), wherein the complement is identical in length to (a).

7. The method of claim 6 , wherein the target cell is in vitro.

8. The method of claim 6 , wherein the target cell is in vivo.

9. The method of claim 6 , wherein a subject comprises the target cell.

10. The method of claim 6 , wherein the virus is hepatitis B virus.

Assignments (2)
SECURITY INTEREST Recorded Dec 15, 2017
From: ROSETTA GENOMICS INC.; ROSETTA GENOMICS LTD; MINUET DIAGNOSTICS, INC.; CYNOGEN INC.
To: GENOPTIX, INC.
Reel/Frame 044899/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2010
From: BENTWICH, ITZHAK; AVNIEL, AMIR; AHARONOV, RANIT; KAROV, YAEL; AVNI, YONAT SHEMER; LEVY, ASAF
To: ROSETTA GENOMICS, LTD.
Reel/Frame 024110/0621 →